What is the effect of Botulinum toxin (Botulinum toxin type A) in the upper lip, Depressor Anguli Oris (DAO), and mentalis areas for a typical adult patient seeking cosmetic improvement?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: January 13, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Cosmetic Effects of Botulinum Toxin in the Upper Lip, DAO, and Mentalis

Botulinum toxin injections in the upper lip, depressor anguli oris (DAO), and mentalis muscles produce specific aesthetic improvements by temporarily paralyzing these muscles, resulting in reduced perioral wrinkles, elevated mouth corners, and smoothing of chin dimpling.

Mechanism of Action

Botulinum toxin type A blocks acetylcholine release at the neuromuscular junction, causing temporary muscle paralysis that lasts weeks to months 1, 2. This reversible paralysis of targeted facial muscles reduces dynamic wrinkles and modifies facial contours 3.

Specific Treatment Areas and Effects

Upper Lip (Perioral Region)

  • Reduces vertical lip lines ("smoker's lines" or perioral rhytids) by weakening the orbicularis oris muscle 4
  • Softens the appearance of a gummy smile when injected into the levator labii superioris, reducing excessive gingival display 5
  • Prevents downward nasal tip sagging through strategic injection points 5
  • Treatment of the perioral area is now routinely performed and contributes to overall facial aesthetic improvement 4

Depressor Anguli Oris (DAO)

  • Elevates the corners of the mouth by weakening the downward pull of the DAO muscle 4
  • Reduces marionette lines (lines extending from mouth corners downward) 5
  • Creates a more pleasant, less sad facial expression by preventing the downturned mouth appearance 6
  • The DAO is a key muscle for addressing lower facial aesthetics 4

Mentalis Muscle

  • Smooths chin dimpling and "pebbled chin" appearance caused by mentalis hyperactivity 6, 5
  • Reduces the appearance of a dimpled chin that occurs with certain facial expressions 6
  • Approximately 30.5% of patients in full-face treatment protocols receive mentalis injections 5

Clinical Considerations and Safety

Dosing and Technique

  • Full-face treatment protocols typically use 113.8 ± 17.6 units total of onabotulinumtoxinA across multiple facial areas 5
  • Individualized dosing per injection site varies by muscle size, strength, and desired effect 6
  • Men generally require higher doses than women due to greater muscle mass 4

Common Pitfalls

  • Unwanted diffusion from mentalis to depressor labii inferioris can occur, causing asymmetric lower lip movement 5
  • This complication occurred in 5 of 189 patients (2.6%) in one large series, but all cases were minor and self-limited 5
  • Proper injection technique and anatomical knowledge are essential to avoid diffusion to adjacent muscles 6

Safety Profile

  • These lower facial treatments are safe when performed correctly, with complication rates around 3.2% in full-face protocols 5
  • All reported complications were minor and temporary, resolving without intervention 5
  • The treatment has been confirmed as effective and safe in both short and long-term use 6

Treatment Integration

  • Combination therapy using botulinum toxin with fillers or lasers produces optimal aesthetic results 4
  • Full-face approaches that include upper lip, DAO, and mentalis treatment are increasingly prevalent and lead to excellent overall outcomes 5
  • Treatment of these advanced facial areas requires greater anatomical understanding compared to traditional upper face injections 4

References

Guideline

Toxin Classification and Mechanisms

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Pathophysiology and Clinical Effects of Botulism

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Botulinum A exotoxin use in clinical dermatology.

Journal of the American Academy of Dermatology, 1996

Research

Update on botulinum toxin.

Seminars in cutaneous medicine and surgery, 2006

Related Questions

How can I make Botox (Botulinum toxin) last longer?
What is the recommended dosage and administration of botulinum toxin type A (Botox) for aesthetic purposes in medicine?
What is the standard protocol for administering Botox (Botulinum toxin) for cosmetic purposes?
What is the recommended dosage and administration of Botulinum toxin type A (Botox) for cosmetic improvement in a typical adult patient for the upper lip, Depressor Anguli Oris (DAO), and mentalis muscles?
What is the effect of botulinum toxin (Botulinum Toxin Type A) in the upper lip depressor anguli oris (DAO) and mentalis muscles in a typical adult patient?
What is the recommended dosage and administration of Botulinum toxin type A (Botox) for cosmetic improvement in a typical adult patient for the upper lip, Depressor Anguli Oris (DAO), and mentalis muscles?
What could be causing a 54-year-old female's joint pain, numbness in her fingers, and longstanding lower back pain, given her history of deep vein thrombosis (DVT), superficial vein thrombosis, hypertension managed with Amlodipine (amlodipine besylate) 10mg daily, and a history of deafness in one ear with a perforated eardrum?
What is the recommended methylprednisolone (corticosteroid) dosage for an adult patient with moderate to severe Acute Respiratory Distress Syndrome (ARDS)?
How should Coumarin be managed in a patient with a history of blood clots or atrial fibrillation, considering age, weight, and renal function?
What is the recommended dosage of intravenous (IV) methylprednisolone (a corticosteroid) for an adult patient with moderate to severe Acute Respiratory Distress Syndrome (ARDS) and acute kidney injury (Impaired renal function)?
What is the cause of Rowell syndrome, a condition characterized by the coexistence of lupus erythematosus (Systemic Lupus Erythematosus, SLE) and rheumatoid arthritis (RA) in a patient, particularly in women of childbearing age?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.